EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-SA 4.0

PD-L1 promotes oncolytic virus infection via a metabolic shift that inhibits the type I IFN pathway

Jonathan J Hodgins iD, John Abou-Hamad iD, Colin Edward O'Dwyer iD, Ash Hagerman iD, Edward Yakubovich iD, Christiano Tanese de Souza iD, Marie Marotel iD, Ariel Buchler iD, Saleh Fadel iD, Maria M Park iD, Claire Fong-McMaster iD, Mathieu F Crupi iD und 14 weitere

Journal of Experimental Medicine · 2024

DOI: 10.1084/jem.20221721 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Experimental Medicine, 2024. Verfasst von Jonathan J Hodgins und 25 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Therapeutics Program, Ottawa Hospital Research Institute , Ottawa, Canada. Hauptthemen laut MEDLINE: B7-H1 Antigen, Interferon Type I, Oncolytic Virotherapy, Oncolytic Viruses. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 90 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-SA 4.0). Gefördert von: CIHR, Ride for Dad, Cancer Research Society.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

While conventional wisdom initially postulated that PD-L1 serves as the inert ligand for PD-1, an emerging body of literature suggests that PD-L1 has cell-intrinsic functions in immune and cancer cells. In line with these studies, here we show that engagement of PD-L1 via cellular ligands or agonistic antibodies, including those used in the clinic, potently inhibits the type I interferon pathway in cancer cells. Hampered type I interferon responses in PD-L1–expressing cancer cells resulted in enhanced efficacy of oncolytic viruses in vitro and in vivo. Consistently, PD-L1 expression marked tumor explants from cancer patients that were best infected by oncolytic viruses. Mechanistically, PD-L1 promoted a metabolic shift characterized by enhanced glycolysis rate that resulted in increased lactate production. In turn, lactate inhibited type I IFN responses. In addition to adding mechanistic insight into PD-L1 intrinsic function, our results will also help guide the numerous ongoing efforts to combine PD-L1 antibodies with oncolytic virotherapy in clinical trials.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

B7-H1 AntigenInterferon Type IOncolytic VirotherapyOncolytic VirusesAnimalsFemaleHumansMiceCell Line, TumorGlycolysisLactic AcidNeoplasmsSignal TransductionMale

Substanzen

B7-H1 AntigenCD274 protein, humanInterferon Type ILactic Acid

Autor:innen und Institutionen

  • Cancer Therapeutics Program, Ottawa Hospital Research Institute , Ottawa, Canada.
  • Department of Biochemistry, Microbiology, and Immunology, University of Ottawa, Ottawa, Canada.
  • Center for Infection, Immunity, and Inflammation, University of Ottawa , Ottawa, Canada.
  • Department of Cellular and Molecular Medicine, University of Ottawa, Ottawa, Canada.
  • Department of Chemistry and Biomolecular Sciences, University of Ottawa, Ottawa, Canada.
  • University of Ottawa Heart Institute , Ottawa, Canada.

ORCID-Profile: Jonathan J Hodgins, John Abou-Hamad, Colin Edward O'Dwyer, Ash Hagerman, Edward Yakubovich, Christiano Tanese de Souza, Marie Marotel, Ariel Buchler, Saleh Fadel, Maria M Park, Claire Fong-McMaster, Mathieu F Crupi, Olivia Joan Makinson, Reem Kurdieh, Reza Rezaei, Harkirat Singh Dhillon, Carolina S Ilkow, John C Bell, Mary-Ellen Harper, Benjamin H Rotstein, Rebecca C Auer, Barbara C Vanderhyden, Luc A Sabourin, Marie-Claude Bourgeois-Daigneault, David P Cook, Michele Ardolino

Förderung

  • CIHR
  • Ride for Dad
  • Cancer Research Society
  • Charles Best Canada Graduate Scholarships Doctoral
  • Ontario Graduate Scholarship
  • BioCanRx
  • Canadian Allergy, Asthma, and Immunology Foundation
  • University of Ottawa Heart Institute

Zitieren

APA

Hodgins, J. J., Abou-Hamad, J., O'Dwyer, C. E., Hagerman, A., Yakubovich, E., Tanese de Souza, C., Marotel, M., Buchler, A., Fadel, S., Park, M. M., Fong-McMaster, C., Crupi, M. F., Makinson, O. J., Kurdieh, R., Rezaei, R., Dhillon, H. S., Ilkow, C. S., Bell, J. C., Harper, M. E., …, & Ardolino, M. (2024). PD-L1 promotes oncolytic virus infection via a metabolic shift that inhibits the type I IFN pathway. Journal of Experimental Medicine. https://doi.org/10.1084/jem.20221721

Vancouver

Hodgins JJ, Abou-Hamad J, O'Dwyer CE, Hagerman A, Yakubovich E, Tanese de Souza C, et al. PD-L1 promotes oncolytic virus infection via a metabolic shift that inhibits the type I IFN pathway. Journal of Experimental Medicine. 2024. doi:10.1084/jem.20221721

BibTeX
@article{Hodgins2024,
  author = {Hodgins, Jonathan J and Abou-Hamad, John and O'Dwyer, Colin Edward and Hagerman, Ash and Yakubovich, Edward and Tanese de Souza, Christiano and Marotel, Marie and Buchler, Ariel and Fadel, Saleh and Park, Maria M and Fong-McMaster, Claire and Crupi, Mathieu F and Makinson, Olivia Joan and Kurdieh, Reem and Rezaei, Reza and Dhillon, Harkirat Singh and Ilkow, Carolina S and Bell, John C and Harper, Mary-Ellen and Rotstein, Benjamin H and Auer, Rebecca C and Vanderhyden, Barbara C and Sabourin, Luc A and Bourgeois-Daigneault, Marie-Claude and Cook, David P and Ardolino, Michele},
  title = {PD-L1 promotes oncolytic virus infection via a metabolic shift that inhibits the type I IFN pathway},
  journal = {Journal of Experimental Medicine},
  year = {2024},
  doi = {10.1084/jem.20221721}
}
Kostenlos starten →